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Process	Mining	to	Explore	Variation	in	Chemotherapy	Pathways	for	Breast	
Cancer	Patients	
Authors:	Angelina	Kurniati,	Geoff	Hall,	David	Hogg,	Owen	Johnson		
		
Abstract		
Background		
There	is	concern	that	standard	chemotherapy	pathways	of	six	cycles	scheduled	every	two	or	
four	weeks	reflect	administrative	and	operational	needs	rather	than	patients’	personal	and	
biological	 needs.	 Process	 mining	 of	 routine	 data	 can	 help	 identify	 and	 explore	 common	
pathway	variants.		
Methods		
We	extracted	anonymised	records	from	routine	data	at	Leeds	Cancer	Centre	for	breast	cancer	
patients	 with	 a	 first	 diagnosis	 between	 2004	 and	 2013	 with	 an	 adjuvant	 chemotherapy	
pathway	(n=738).	This	produced	an	event	log	data	file	(containing	events,	dates	and	times)	
which	was	analysed	using	the	ProM	process	mining	tool	(www.promtools.org).	We	used	the	
Inductive	 Miner	 plug-in	 and	 constructed	 statistical	 and	 visual	 models	 of	 the	 clinical	
pathways.	The	data	covered	a	ten-year	period	and	we	created	multiple	splits	of	the	event	log	
to	examined	statistically	significant	variations	over	time.		
Results		
Most	 patients	 varied	 from	 the	 expected	 pathway	 (712	 variants	 for	 738	 patients).	 We	
produced	a	pathway	model	which	included	these	variants	and	checked	conformance.	Overall	
fitness	of	data	to	model	was	high	(97.1%)	but	we	noted	significant	changes	to	the	fit	in	2006	
(a	5.1%	change)	and	2011	 (8.9%	change)	which	 require	 further	 investigation.	 In	 total	51%	
(n=376)	of	patients	did	complete	all	six	cycles,	less	than	half	(21%	of	total,	n=158)	completed	
the	 cycles	 without	 an	 adverse	 event	 while	 many	 (30%,	 n=218)	 experienced	 at	 least	 one	
adverse	 event	 including	 missed	 appointments,	 neutropenic	 sepsis	 and	 emergency	
admissions.	Of	the	49%	(n=362)	who	did	not	complete	six	cycles,	28%	(n=207)	experienced	
adverse	events	with	the	remainder	(21%,	n=155)	not	completing	for	other	reasons.		
Conclusions		
Process	mining	 of	 routine	 data	 showed	 extensive	 variation	 from	 standard	 chemotherapy	
pathways	 including	 incomplete	 treatment	 and	 adverse	 events.	 Future	 work	 is	 needed	 to	
explore	potential	causal	links	and	understand	changes	in	the	pathway	over	time.		
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